What's Happening?
Pfizer has announced promising results from its Phase 3 TALAPRO-3 study, which evaluated the combination of TALZENNA (talazoparib) and XTANDI (enzalutamide) in men with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive
prostate cancer (mCSPC). The study demonstrated a 52% reduction in the risk of radiographic progression or death compared to placebo plus XTANDI. At three years, the radiographic progression-free survival (rPFS) rate was estimated at 77% for patients treated with the combination, compared to 56% for those on placebo. The study's findings were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting and published in The New England Journal of Medicine.
Why It's Important?
The results of the TALAPRO-3 study are significant as they offer a new potential treatment option for patients with HRR gene-mutated mCSPC, a group that often experiences poorer outcomes. The combination of TALZENNA and XTANDI could delay progression to castration-resistant disease, which is the most symptomatic and lethal phase of prostate cancer. This development underscores the importance of genetic testing in routine care and highlights the potential for this combination therapy to improve patient outcomes significantly. The study's findings could lead to changes in clinical practice and provide patients with more time before disease progression.
What's Next?
Pfizer is discussing the results with global health authorities to potentially expand the combination regimen's existing indication. The trial remains ongoing, and overall survival will be formally assessed at the final analysis. The combination of TALZENNA and XTANDI is already approved in more than 60 countries for other indications, and these new findings could lead to broader approval and adoption in treating HRR gene-mutated mCSPC.
